Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways

Fig. 5

Western blot analysis of E-cadherin, β-catenin, and vimentin expression in (a) SKBR3 and (b) ZR75 cells under the effect of DA (5 µM) and BMS-202 (5 µM) for 48 h. It is evident that treatment with both DA and BMS-202 upregulates E-cadherin in both cell lines while downregulating β-catenin and vimentin expression in comparison with DA and BMS-202 treatment alone and their matched control. GAPDH was used as a loading control. Cells were treated with DA and BMS-202 for 48 h, as illustrated in the materials and methods section. Data are expressed as protein expression ± SEM

Back to article page